Highlights Alkermes plc

Equities

ALKS

IE00B56GVS15

Real-time Estimate Cboe BZX Other stock markets 17:16:04 26/06/2024 BST			5-day change	1st Jan Change
24.24 ^USD	+0.27%		-3.15%	-12.55%

06-17	TD Cowen Initiates Alkermes at Buy With $34 Price Target	MT
06-11	Transcript : Alkermes plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:40 AM

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tranche Update on Alkermes plc's Equity Buyback Plan announced on November 21, 2007.	05-01	CI
Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	05-01	MT
Earnings Flash (ALKS) ALKERMES Reports Q1 Revenue $350.4M, vs. Street Est of $360.3M	05-01	MT
Earnings Flash (ALKS) ALKERMES Posts Q1 EPS $0.43, vs. Street Est of $0.58	05-01	MT
Alkermes plc Reiterates Earnings Guidance for the Year 2024	05-01	CI
Alkermes plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	04-09	MT
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	04-09	MT
Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	04-09	CI
Tranche Update on Alkermes plc's Equity Buyback Plan announced on November 21, 2007.	02-21	CI
Alkermes Shares Rise After Q4 Results, Guidance	02-15	MT
Alkermes Q4 Non-GAAP Earnings, Revenue Increase; 2024 Outlook Issued -- Shares Gain Pre-Bell	02-15	MT
Earnings Flash (ALKS) ALKERMES Posts Q4 Revenue $377.5M, vs. Street Est of $362.4M	02-15	MT
Alkermes plc announces an Equity Buyback for $400 million worth of its shares.	02-15	CI
Alkermes plc Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
Alkermes plc Provides Earnings Guidance for the Year 2024	02-15	CI
Alkermes plc s Equity Buyback announced on November 21, 2007 has expired with repurchase of 8,866,342 shares, representing 8.68% for $114 million.	02-14	CI
Alkermes plc authorizes a Buyback Plan.	02-14	CI
Alkermes plc Announces Topline Results from Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI	01-03	CI
Alkermes to Sell Ireland Facility to Novo Nordisk	12-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alkermes plc

Equities

ALKS

IE00B56GVS15

Highlights

Filters